D3 Bio Announces Oral Presentation of Clinical Data for D3S-001 at the 2025 AACR Annual Meeting

Shanghai, China — April 21, 2025 — D3 Bio, a global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, announced that its abstract highlighting clinical data for D3S-001, the company’s lead program, has been selected for an oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, Illinois.

The presentation will be part of the Clinical Trials Minisymposium session titled “Innovative Approaches to Key Molecular Targets”, scheduled for April 29, 2025, from 2:30 PM to 4:30 PM CDT. The abstract, identified by presentation number CT266, will be published and cited with this number in the AACR meeting proceedings.

D3S-001 is a new generation KRAS G12C inhibitor designed to enhance KRAS G12C target engagement. The data to be presented at AACR 2025 will highlight clinical efficacy and safety results from ongoing Phase 1/2 trials, demonstrating promising anti-tumor activity and favorable tolerability in patients with advanced or metastatic non-small cell lung cancer, who are resistant to first generation KRAS G12C inhibitors, along with PK and biomarker analyses.

“We are honored to have the opportunity to present our latest clinical data for D3S-001 at the AACR Annual Meeting, one of the most prestigious forums for cancer research,” said Herbert H F Loong, Deputy Medical Director, Phase 1 Clinical Trial Centre of The Chinese University of Hong Kong. “These findings underscore the potential of D3S-001 to address significant unmet needs in cancer treatment, and we look forward to sharing our progress with the scientific and medical community.”

The AACR Annual Meeting is the largest and most comprehensive cancer research event, bringing together researchers, clinicians, and industry leaders from around the world to share the latest advances in cancer science and medicine.

For more information about the AACR Annual Meeting 2025, please visit https://www.aacr.org/meeting/aacr-annual-meeting-2025/.

‍

‍

About D3S-001

D3S-001 is a new generation KRAS G12C inhibitor designed to enhance KRAS G12C target engagement. In preclinical investigations, D3S-001 has demonstrated high covalent potency, ability to rapidly and completely engage the KRAS G12C target at clinically relevant doses, and CNS penetration properties. D3S-001 is currently in a Phase II global clinical trial in patients with advanced solid tumors harboring a KRAS G12C mutation, including Non-Small Cell Lung Cancer (NSCLC), colorectal cancer (CRC) and other tumor types. For detailed information about D3S-001, please refer to the following.

• Research Article published at the 2024 September issue of Cancer Discovery, titled “D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities”, Cancer Discov (2024) 14 (9): 1675–1698. https://doi.org/10.1158/2159-8290.CD-24-0006.
• Phase I dose escalation data published at ESMO 2024, titled “615MO - Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/ metastatic solid tumors with KRAS G12C mutations”, https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/phase-i-ii-study-of-d3s-001-a-second-generation-kras-g12c-inhibitor-in-advanced-metastatic-solid-tumors-with-kras-g12c-mutations.

About D3 Bio

D3 Bio is a global biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology. The D3 Bio discovery and development platform leverages our proprietary clinical insight and biomarker strategy to guide our discovery and development efforts in creating novel and clinically meaningful new therapies for patients in need.

‍

‍

Media Contact:

Rui Liu
Head, Corporate Affairs
bd@d3bio.com
Shanghai, China

‍